Suritozole (also known as MDL 26,479) is an aryldialkyltriazolethione derivative patented by Merrell Dow Pharmaceuticals, Inc as an antidepressant. Suritozole acts as negative modulator at the gamma-aminobutyric acid A (GABAA) receptor that enhances cholinergic function. In preclinical models, chronic treatment Suritozole produces a small but significant decrease in the average spontaneous firing rate of Purkinje neurons. Suritozole attenuated a scopolamine-induced acquisition deficit in a T-maze reinforced alternation task, suggesting that the compound may have memory enhancing potential.